Comparing Dopamine, Norepinephrine and Epinephrine for Pulmonary Hypertension Crisis
Compares dopamine, norepinephrine and epinephrine in adults in pulmonary hypertension crisis.
Plain-language title generated from the registry record
Registry title: Vasopressor Agents in Pulmonary Hypertension Crisis
Key facts
- Where
- Beijing, Guangzhou, and Wuhan, ChinaSee the 3 sites
Where in China
- Chinese Academy of Medical Sciences, Fuwai HospitalBeijing, ChinaTaking people
- Guangdong Provincial People's HospitalGuangzhou, ChinaNot yet recruiting
- Zhongnan Hospital of Wuhan UniversityWuhan, ChinaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- China National Center for Cardiovascular Diseases
- Trial code
- NCT07667829
- Record updated
- 30 October 2026
- Original description
Comparison of the efficacy and safety of three vasoactive agents-dopamine, norepinephrine, and epinephrine-in the treatment of patients with pulmonary hypertension crisis: prospective, randomised controlled trial monitored by haemodynamic monitoringRead full original descriptionShow less
Comparison of the Efficacy and Safety of Dopamine, Norepinephrine and Epinephrine in the Treatment of Pulmonary Hypertensive Crisis Under Hemodynamic Monitoring
Comparison of the efficacy and safety of three vasoactive agents-dopamine, norepinephrine, and epinephrine-in the treatment of patients with pulmonary hypertension crisis: prospective, randomised controlled trial monitored by haemodynamic monitoring
Inclusion: Age > 18 years old; Signed informed consent form; Confirmed diagnosis of arterial pulmonary hypertension (PAH) and/or chronic thromboembolic pulmonary hypertension (CTEPH); Presenting with manifestations of pulmonary hypertensive crisis; Receiving both diagnosis and treatment in-hospital; No intravenous administration of the vasopressor drugs (including dopamine, norepinephrine, and epinephrine) under study at enrollment.
Exclusion: Ongoing use of monoamine oxidase inhibitor (MAOI) antidepressants or anti-Parkinson drugs (phenelzine, tranylcypromine, isocarboxazid, moclobemide); Already receiving the vasopressor drugs (dopamine, norepinephrine, epinephrine) under study at enrollment; Hypersensitivity to the study drug; At SCAI stage D or stage E ; Patients who only receive a diagnosis but no treatment in the hospital; Uncontrolled hyperthyroidism; Complicated with angle-closure glaucoma; Ongoing use of halogenated hydrocarbon general anesthetics such as cyclopropane and halothane; Pregnancy.